We are pleased to announce our latest news to you.
admedicum and the German Society for Muscular Diseases (DGM) are proud to announce a joint development called patient2care
We are pleased to be working a partner that is such a competent and recognized patient organization to develop a first application for patient2care
Hopefully you share our perspective that patient engagement should be fully integrated into drug development. If you know anyone that needs convincing that effective patient engagement in the industry matters, here is our list
Patient preferences are used by Industry, Regulators, HTA/payers, academics, physicians, patients to inform decision making regarding topics like benefit/risk assessment, labeling, early access, and relevant endpoints
patient2site: Technology combined with unmatched patient engagement services to create successful patient recruitment strategies, trial awareness and boost enrollment.
Patient Partnering in Clinical Development (PPCD) 2021 is focusing on how this influences the patient’s journey and involvement as partners and what we have learnt to put in place for the next steps to the new norm!
In a number of projects admedicum and Justin Stindt Consulting have already successfully merged their expertise. The companies now are combining their skills tighter to create value for both patients and industry.
Following continuous growth and internationalisation of collaboration with patients and companies across Europe we are excited to announce the opening of admedicum Paris, France.
It’s time for Europe to bridge the gap in newborn screening for spinal muscular atrophy. The European Alliance for Newborn Screening in Spinal Muscular Atrophy calls upon the government of Europe to include a test for SMA in national newborn screening programmes.
The patient association MPS España and the patient engagement expert group admedicum Business for Patients are excited to announce their strategic partnership.
Attention deficit hyperactivity disorder, or ADHD for short, is often associated with children. Only a few think of affected adults! The symptoms persist, at least in part, in 50-80% of those affected as children into adulthood, often with far-reaching consequences. Their care urgently needs to be improved - leading experts agreed on this during an expert discussion. Approaches for improving care were also discussed during the meeting. The discussion was supported by Takeda, a company active in the field of ADHD.